Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis.
BACKGROUND
Effective symptom control is a primary concern of most heartburn suffers.


OBJECTIVE
To compare the safety and efficacy of pantoprazole, placebo and the H2 antagonist nizatidine in relieving symptoms in patients with erosive oesophagitis.


METHODS
Data from two randomized, double-blind studies were pooled. Patients received pantoprazole 10, 20 or 40 mg, or placebo daily (study 1, n = 603), or pantoprazole 20 or 40 mg daily or 150-mg nizatidine b.d. (study 2, n = 243) for either 4 or 8 weeks. Endoscopy was performed at baseline, week 4 and week 8. Persistent absence of symptoms was defined as the first day that no symptoms were reported by the patient on that day or any subsequent study day.


RESULTS
A significantly higher percentage (P < 0.05) of pantoprazole patients reported elimination of all symptoms by week 8. Daytime heartburn, night-time heartburn and regurgitation were significantly better controlled with pantoprazole (with a dose-response at most time-points). Absence of symptoms was a powerful predictor of healing; presence of symptoms correlated poorly.


CONCLUSIONS
Pantoprazole is more effective than placebo or nizatidine for controlling heartburn and acid regurgitation in patients with erosive oesophagitis. Relief of GERD symptoms is highly predictive of healing of erosive oesophagitis at 4 and 8 weeks.
Bochenek
W J
WJ
Clinical Research and Development, Wyeth Research, Collegeville, PA, USA.
Mack
M E
ME
Fraga
P D
PD
Metz
D C
DC
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000368:Aged; D000863:Antacids / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D004311:Double-Blind Method; D004941:Esophagitis / Q000188:drug therapy*; D005260:Female; D005764:Gastroesophageal Reflux / Q000517:prevention & control; D006356:Heartburn / Q000517:prevention & control; D016481:Helicobacter Infections; D016480:Helicobacter pylori; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D016567:Nizatidine / Q000627:therapeutic use; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000077402:Pantoprazole; D016032:Randomized Controlled Trials as Topic; D013454:Sulfoxides / Q000627:therapeutic use*; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000863:Antacids; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D006635:Histamine H2 Antagonists; D013454:Sulfoxides; D000077402:Pantoprazole; D009853:Omeprazole; D016567:Nizatidine